{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:56:33Z","timestamp":1791597393114,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105575","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T01:52:18Z","timestamp":1756432338000},"page":"105575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients\u2014exploratory results from TITAN-RCC"],"prefix":"10.1016","volume":"10","author":[{"given":"A.","family":"Fritzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"R\u00f6ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Wehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-O.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.esmoop.2025.105575_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105575_bib2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105575_bib3","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105575_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105575_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105575_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41574-024-01077-6","article-title":"Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors","volume":"21","author":"Iwama","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105575_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12094-020-02397-5","article-title":"Anti-PD-1\/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis","volume":"23","author":"Park","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105575_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003965","article-title":"Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis","volume":"10","author":"Kawai","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of Immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.esmoop.2025.105575_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105575_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2326-6066.CIR-13-0016","article-title":"Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production","volume":"1","author":"de Coa\u00f1a","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.esmoop.2025.105575_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J Transl Med"},{"key":"10.1016\/j.esmoop.2025.105575_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105575_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and Treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105575_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.smim.2011.01.007","article-title":"T cell receptor recognition of self and foreign antigens in the induction of autoimmunity","volume":"23","author":"Wucherpfennig","year":"2011","journal-title":"Semin Immunol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105575_bib17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor\u2013induced toxic effects with shared cancer and tissue antigens in non\u2013small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105575_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105575_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105575_bib21","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2025.105575_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991433","article-title":"Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105575_bib23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105575_bib24","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105575_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105575_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009215","article-title":"Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma","volume":"12","author":"Borgers","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2025.105575_bib27","article-title":"Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105575_bib28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105575_bib29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.esmoop.2025.105575_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.610952","article-title":"Efficacy and feasibility of programmed death-1\/programmed death ligand-1 blockade therapy in non-small cell lung cancer patients with high antinuclear antibody titers","volume":"11","author":"Mouri","year":"2021","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105575_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012641","article-title":"Association between changes in the patterns of antinuclear autoantibodies during immune checkpoint inhibition therapy and the development of severe immune related adverse events","volume":"23","author":"Alserawan","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105575_bib33","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105575_bib34","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"Recommendations guiding physicians in biomedical research involving human subjects","volume":"277","year":"1997","journal-title":"J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105575_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jalm\/jfab140","article-title":"The international consensus on ANA patterns (ICAP) in 2021\u2014the 6th workshop and current perspectives","volume":"7","author":"Chan","year":"2022","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.esmoop.2025.105575_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non\u2013small cell lung cancer patients positive for antinuclear antibodies","volume":"130","author":"Yoneshima","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"de Moel","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105575_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100415","article-title":"The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study","volume":"7","author":"Izawa","year":"2022","journal-title":"ESMO Open"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105575_bib40","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1002\/cam4.4675","article-title":"Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study","volume":"11","author":"Barth","year":"2022","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105575_bib41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti\u2013PD-1 therapy for advanced non\u2013small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib42","first-page":"81","article-title":"Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab","volume":"11","author":"Giannicola","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13046-023-02851-6","article-title":"Autoimmune paneLs as prEdictors of toxicity in patients TReated with immune checkpoint inhibiTors (ALERT)","volume":"42","author":"Genta","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105575_bib44","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting antinuclear antibodies","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105575_bib45","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/j.clgc.2022.04.002","article-title":"Preexisting autoantibodies and immune related adverse events in metastatic urothelial carcinoma patients treated by pembrolizumab","volume":"20","author":"Castel-Ajgal","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105575_bib46","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.21037\/tlcr-22-464","article-title":"Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study","volume":"11","author":"Zhang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105575_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Daban","year":"2023","journal-title":"OncoImmunology"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:59:41Z","timestamp":1772895581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014449"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105575","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients\u2014exploratory results from TITAN-RCC","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105575"}}